RPE65

Across TCGA pan-cancer cohorts, RPE65 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPE65 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RPE65 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPE65 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

ESCA, UCEC, and SCLC are the cancer types where RPE65 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.124	0.703	<.001	30	view →
UCEC	DFS	Median	II,III,IV	1.000	0.427	.003	30	view →
SCLC	DFS	Median	All	0.192	0.637	.003	24	view →
STAD	OS	Median	II,III,IV	0.251	0.659	.040	12	view →
HNSC	OS	Median	II,III,IV	0.196	0.710	.023	9	view →
LUAD	OS	Median	All	0.405	0.703	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.082	0.429	.008	6	view →
LUSC	DFS	Median	All	1.000	0.636	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPE65–ESCA (OS)

Open the ESCA breakdown →